Cellular Intelligence has acquired global rights to the STEM-PD cell therapy program for Parkinson's disease from Novo Nordisk (NVO), Cellular Intelligence said Monday.

Financial terms were not provided.

Cellular Intelligence said Novo Nordisk will make an equity investment in the company and remain eligible for future milestone payments and royalties.

The allogeneic therapy has completed Phase 1/2 dosing and has an FDA-cleared investigational new drug application for Phase 2 development, along with Fast Track designation, according to the company.

Cellular Intelligence also named Nuno Mendonca as chief medical officer to oversee clinical development of the program.

Novo Nordisk did not immediately respond to a request for comment from MT Newswires.

Price: 47.14, Change: +1.07, Percent Change: +2.31